Annovis Bio appoints William Fricker as interim CFO effective December 4, 2024

Annovis Bio, Inc.

William Fricker, 61, appointed interim CFO; most recently CFO of NeuroTrauma Sciences (Dec 2023-Apr 2024).
Previously CFO at NRX Pharmaceuticals (2020-2021), taking it public, and CAO at Immunomedics (2018-2020) until sale to Gilead.
Fricker served as independent CFO contractor for biotech firms from 2021-2023; CPA (inactive), started career at PwC.
No related-party transactions; Fricker serves on contract basis without employment agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.